Taiwan, No Longer a Life-Sciences Island Unto Itself - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Taiwan, No Longer a Life-Sciences Island Unto Itself
Taking a cue from its electronics industry, Taiwan is seeking to put its biotechnology and pharmaceutical industries on the map. An interactive map shows pharmaceutical activity in Taiwan.


Pharmaceutical Technology
Volume 33, Issue 5

Information resources

A plethora of information resources are available for life-science companies and their suppliers interested in doing business in Taiwan. Below is a resource list provided by TAITRA:

  • Biotechnology and Pharmaceutical Industries Association Program Office, Taiwan's Ministry of Economic Affairs (MOEA) is responsible for promoting and implementing the government's biotech-related plan and strategies and serves as the international communications vehicle for the industry. http://www.biopharm.org.tw/
  • Overseas Chinese Affairs Commission coordinates with overseas Chinese businesses and facilities business and investment processing. http://www.ocac.gov.tw/
  • Department of Health, Executive Yuan is Taiwan's highest level health administrative body and is responsible for health-administration affairs for the nation as a whole and for instructing, monintoring, and coordinating regional health bodies. http://www.doh.gov.tw/
  • Industrial Development Bureau, MOEA is responsible for industrial development strategies, polices, and related matters such as financial and tax measures, industrial pollution prevention, guidance on industrial security, factory management, and general industrial administrative management. http://www.moeaidb.gov.tw/
  • Intellectual Property Office, MOEA is responsible for patent examination, trademark administration, copyright protection, intellectual property rights, and related information. http://www.moeaipo.gov.tw/
  • Board of Foreign Trade, MOEA provides economic and trade information, import–export services, international and regional economic and trade promotion. http://www.trade.gov.tw/
  • Industrial Development and Economic Investment Center, MOEA promotes Taiwan as an investment destination to overseas investors. http://www.idic.gov.tw/spring.html
  • Department of Industrial Technology, MOEA is responsible for researching and planning industrial technology development strategies, overseeing technology project budgets, promoting the development of high-technology industries, and upgrading of local industries. http://doit.moea.gov.tw/.
  • Economic Processing Zone Administration, MOEA is responsible for investments in designated zones, engages in foreign trade and sales, company registration, and affairs relating to labor, construction, and land. http://www.epza.gov.tw/
  • Department of Commerce, MOEA is responsible for drawing up of business policies and laws, business planning, managing, guiding, monitoring, and researching business contracts, business taxes, and business registration. http://www.moea.gov.tw/~meco/doc/ndoc/default.htm
  • Investment Commission, MOEA is responsible for overseas investments, technological collaborations, and examination of foreign investments. http://www.moeaic.gov.tw/
  • Hsinchu Science-Based Industrial Park Administration is responsible for investments, locating land and factories, research-development grants, and personnel training. http://www.sipa.gov.tw/index_apis.php
  • Taiwan External Trade Development Council (TAITRA) provides customized trade and investment services to domestic and overseas enterprises. http://www.taiwantrade.com.tw/cgi-bin/bv60/TWTRADE/index_tc.jsp
  • Overseas Chinese Enterprises Commission promotes joint ventures between overseas Chinese firms and local companies.
  • Taiwan Venture Capital Association conducts surveys to local and overseas venture capital industries, lobbies on behalf of the industry, serves as a bridge between members and high-technology companies,and provides investment-related industrial information to members. http://www.tvca.org.tw/
  • Taiwan Pharmaceutical Development Association promotes the development of production technology, research and development, business management, and international exchange to enhance Taiwan's pharmaceutical industry.
  • Taiwan Pharmaceutical Manufacturer's Association is responsible for increasing the quality and stability of locally produced pharmaceutical products, works on research and development of new medicines, promotes the industry, strengthens overseas collaboration and investments, expanding overseas markets, and provides communication between the pharmaceutical industries of Taiwan and China. http://www.tpma.org.tw/.
  • International Research-Based Pharmaceutical Manufacturers Associations consists of US, European, and Japanese pharmaceutical companies doing business in Taiwan. http://www.irpma.org.tw/
  • Biotechnology New Drug Industry (Enacted on 2007/06/15) (http://lis.ly.gov.tw/npl/fast/02814/960614.htm)

For information on Taiwan's recent efforts to strengthen protection of intellectual property, see the online exclusive, "Taiwan Seeks to Strengthen its Intellectual Property Goverance"

References

1. PricewaterhouseCoopers, "The Changing Dynamics of Pharma Outsourcing in Asia," (New York, NY, 2008).

2. A. Drakulich and P. Van Arnum, "Evaluating Pieces of the Pharma Supply Chain," Pharm. Technol. 33 (1), 42–54 (2009).

3. ClinicalTrials.gov/, National Library of Medicines, National Institutes of Health (Bethesda, MD), clinicaltrials.gov/, accessed Apr. 13, 2009.

4. P. Van Arnum, "Tipping the Scales in Manufacturing Investment," Pharm. Technol. 32 (7), 40–48 (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here